BIOPROJET-BIOTECH, 4 rue du Chesnay Beauregard, 35762 Saint-Grégoire, France.
Bioorg Med Chem. 2013 Aug 1;21(15):4526-9. doi: 10.1016/j.bmc.2013.05.035. Epub 2013 Jun 2.
Due to its involvement in major CNS functions, the histamine H3 receptor (H3R) is the subject of intensive medicinal chemistry investigation, supported by the range of modern drug discovery tools, such as receptor modeling and ligand docking. Although the receptor models described to date share a majority of common traits, they display discrete alternatives in amino-acid conformation, rendering ligand binding modes quite different. Such variations impede structure-based drug design in the H3R field. In the present study, we used a combination of medicinal chemistry, receptor-guided and ligand-based methods to elucidate the binding mode of antagonists. The approaches converged towards a ligand orientation perpendicular to the membrane plane, bridging Glu206 of the transmembrane helix 5 to acidic amino acids of the extracellular loops. This consensus will help future structure-based drug design for H3R ligands.
由于其参与了主要的中枢神经系统功能,组胺 H3 受体(H3R)是药物化学研究的重点,这得益于一系列现代药物发现工具,如受体建模和配体对接。尽管迄今为止描述的受体模型具有大多数共同特征,但它们在氨基酸构象上显示出离散的替代方案,从而使配体结合模式非常不同。这种变化阻碍了 H3R 领域的基于结构的药物设计。在本研究中,我们使用药物化学、受体导向和基于配体的方法相结合来阐明拮抗剂的结合模式。这些方法集中在配体的取向垂直于膜平面,将跨膜螺旋 5 中的Glu206 与细胞外环中的酸性氨基酸连接起来。这一共识将有助于未来基于结构的 H3R 配体药物设计。